Get started
Author

Yuanyuan Faith Bian

Observed names: Bian, Yuanyuan, Yuanyuan Bian
ORCID: 0000-0003-4736-2597
Observed ORCID: 0000-0003-4736-2597
OpenAlex ID: A5103147019
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025 · Jennifer A. Woyach, Lugui Qiu, et al. · Journal of Clinical Oncology · 23
PDF
SPA: Single patient acceleration in oncology dose-escalation trials
2021 · Gu Mi, Yuanyuan Bian, et al. · Contemporary Clinical Trials · 17
Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
2023 · Antonio Llombart-Cussac, George Sledge, et al. · Cancer Research · 15
Power priors with entropy balancing weights in data augmentation of partially controlled randomized trials
2022 · Guanglei Yu, Yuanyuan Bian, et al. · Journal of Biopharmaceutical Statistics · 11
Exact test-based approach for equivalence test with parameter margin
2017 · Xiaoyu (Cassie) Dong, Yuanyuan Bian, et al. · Journal of Biopharmaceutical Statistics · 10
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study
2025 · Nirav N. Shah, Pier Luigi Zinzani, et al. · Blood Advances · 6
PDF
Effects of an antler point restriction on deer hunter perceptions and satisfaction in Missouri
2018 · Lonnie P. Hansen, Jason A. Sumners, et al. · Wildlife Society Bulletin · 5
A Note on Nonlocal Prior Method
2017 · Bian, Yuanyuan, Wu, Ho-Hsiang · arXiv (Cornell University) · 3
PDF
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study
2026 · Krish Patel, Julie M. Vose, et al. · Blood Advances · 2
PDF
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
2025 · Jennifer Woyach, Lugui Qiu, et al. · Blood · 2
PDF
Mourning dove period and annual survival in west‐central Missouri
2017 · John H. Schulz, Yuanyuan Bian, et al. · Wildlife Society Bulletin · 2
BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
2023 · Jennifer Ann Woyach, Catherine Callaghan Coombs, et al. · Journal of Clinical Oncology · 1
PDF
The RobinCar Family: R tools for robust covariate adjustment in randomized clinical trials
2026 · Marlena Bannick, Yuanyuan Bian, et al. · BMC Medical Research Methodology
Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.
2026 · William G. Wierda, Wojciech Jurczak, et al. · Journal of Clinical Oncology
PDF
A Bayesian model to identify multiple expression patterns with simultaneous FDR control for a multi-factor RNA-seq experiment
2023 · Yuanyuan Bian, Chong He, et al. · Statistical Applications in Genetics and Molecular Biology
Works count: 15
Citation count: 97
H-index: 6
I10-index: 5
Year
Topic
Type